The Group's principal activity is discovering, developing, manufacturing and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. The Group's operations are carried out through two divisions. Elan Drug Technologies focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Biopharmaceuticals relates to the research, development and commercial activities in the areas of autoimmune diseases, neurodegenerative diseases and specialty business. The Group's product brands are Azactam, Maxipime, MXDAS, NanoCrystal, Naprelan, Prialt, SODAS, Tysabri and Verelan.
Alacra Alerts:
Receive alerts on the latest reports on Elan Corporation plc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
